Clinical Trial: The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Brief Summary: Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Detailed Summary:
Sponsor: Samsung Medical Center

Current Primary Outcome: serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ]

We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.


Original Primary Outcome: Same as current

Current Secondary Outcome: to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ]

We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.


Original Secondary Outcome: Same as current

Information By: Samsung Medical Center

Dates:
Date Received: July 16, 2010
Date Started: June 2008
Date Completion:
Last Updated: July 20, 2011
Last Verified: July 2011